💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Strontium Ranelate

CHEMBL3707306 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
513.5 g/mol
LogP
—
Phase
4

Strontium ranelate is a dual-action bone agent used for the treatment of osteoporosis, combining the actions of both inhibiting osteoclast-mediated bone resorption and stimulating osteoblast-mediated bone formation by interacting with the calcium-sensing receptor. By simultaneously reducing bone breakdown and promoting bone synthesis, it improves bone microarchitecture and reduces fracture risk at both vertebral and non-vertebral sites. It has been restricted in some markets due to cardiovascular and venous thromboembolic risks.

分子量

513.5000 g/mol

TPSA

216.00 Ų

治療領域

Osteoporosis

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
N#Cc1c(N(CC(=O)[O-])CC(=O)[O-])sc(C(=O)[O-])c1CC(=O)[O-].[Sr+2].[Sr+2]

                

                

                
                

                    
InChI

                    
InChI=1S/C12H10N2O8S.2Sr/c13-2-6-5(1-7(15)16)10(12(21)22)23-11(6)14(3-8(17)18)4-9(19)20;;/h1,3-4H2,(H,15,16)(H,17,18)(H,19,20)(H,21,22);;/q;2*+2/p-4

                

                

                

                    
                    

                        
Molecular Formula

                        
C12H6N2O8SSr2

                    

                    
                    

                        
HBD / HBA

                        
- / 11

                    

                    
                    

                        
回転可能結合数

                        
4

                    

                    
                    
                    

                        
重原子数

                        
25

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
Strontium ranelate is a dual-action bone agent used for the treatment of osteoporosis, combining the actions of both inhibiting osteoclast-mediated bone resorption and stimulating osteoblast-mediated bone formation by interacting with the calcium-sensing receptor. By simultaneously reducing bone breakdown and promoting bone synthesis, it improves bone microarchitecture and reduces fracture risk at both vertebral and non-vertebral sites. It has been restricted in some markets due to cardiovascular and venous thromboembolic risks.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Strontium Ranelate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3707306.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6918182.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.